

Patrick A Hamilton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/814996/publications.pdf>

Version: 2024-02-01

20
papers

796
citations

933447
10
h-index

839539
18
g-index

20
all docs

20
docs citations

20
times ranked

1347
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. Journal of the American Society of Nephrology: JASN, 2017, 28, 2756-2767.	6.1	448
2	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nature Communications, 2020, 11, 1600.	12.8	120
3	Characteristics and outcomes of hospitalised patients with acute kidney injury and COVID-19. PLoS ONE, 2020, 15, e0241544.	2.5	34
4	A Point-of-Care Immunosensor Based on a Quartz Crystal Microbalance with Graphene Biointerface for Antibody Assay. ACS Sensors, 2020, 5, 3520-3532.	7.8	32
5	The future for diagnostic tests of acute kidney injury in critical care: evidence synthesis, care pathway analysis and research prioritisation. Health Technology Assessment, 2018, 22, 1-274.	2.8	27
6	Long-term outcomes of persistent disease and relapse in primary membranous nephropathy. Nephrology Dialysis Transplantation, 2016, 31, 2108-2114.	0.7	26
7	Successful outcome of pregnancy in patients with anti-neutrophil cytoplasm antibody-associated small vessel vasculitis. Kidney International, 2015, 87, 807-811.	5.2	23
8	Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model. Nephrology Dialysis Transplantation, 2018, 33, 2145-2155.	0.7	15
9	Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-onset incident and relapsing primary membranous nephropathy. Nephrology, 2018, 23, 60-68.	1.6	14
10	Urinary protein selectivity in nephrotic syndrome and pregnancy: resurrection of a biomarker when renal biopsy is contraindicated. CKJ: Clinical Kidney Journal, 2014, 7, 595-598.	2.9	12
11	Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti-PLA ₂ R positive primary membranous nephropathy. Journal of Clinical Apheresis, 2018, 33, 283-290.	1.3	10
12	Chronic anticoagulation is not associated with a reduced risk of acute kidney injury in hospitalised Covid-19 patients. BMC Nephrology, 2021, 22, 224.	1.8	8
13	Associations between human leukocyte antigens and renal function. Scientific Reports, 2021, 11, 3158.	3.3	7
14	The investigative burden of membranous nephropathy in the UK. CKJ: Clinical Kidney Journal, 2020, 13, 27-34.	2.9	6
15	Human leukocyte antigen associations with renal function among ethnic minorities in the United Kingdom. Hla, 2020, 96, 697-708.	0.6	5
16	Transcatheter aortic valve implantation in end-stage renal disease. CKJ: Clinical Kidney Journal, 2012, 5, 247-249.	2.9	4
17	Peptide GAM immunoadsorption in anti-PLA ₂ R positive autoimmune membranous nephropathy. The PRISM trial. Journal of Clinical Apheresis, 2022, 37, 40-53.	1.3	3
18	FP123RESULTS OF SURVEY ON MANAGEMENT OF MEMBRANOUS NEPHROPATHY IN UNITED KINGDOM *ON BEHALF OF UK MN RADAR STEERING GROUP. Nephrology Dialysis Transplantation, 2015, 30, iii108-iii108.	0.7	2

#	ARTICLE	IF	CITATIONS
19	P0412VALUE OF INTERNATIONAL RISK-PREDICTION TOOL IN IGA NEPHROAPTHY : A SINGLE CENTRE STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
20	MO868CLINICAL OUTCOMES FOR INTRAVENOUS DRUG USERS REQUIRING HAEMODIALYSIS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0